Navigation Links
Endologix Responds to Alleged Patent Infringement
Date:10/13/2009

IRVINE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has conducted further evaluation of the patent infringement lawsuit filed against the company last week by Cook Medical, and of the patents asserted in the lawsuit. Based upon this evaluation, Endologix believes that the alleged infringement is without merit and the company intends to vigorously defend its position.

John McDermott, Endologix President and Chief Executive Officer, said, "We are pleased that our initial evaluation of these claims, which Cook Medical waited for years to assert, has already yielded support for numerous promising defenses."

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, specifically related to the claims of alleged infringement. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

    COMPANY CONTACT:                           INVESTOR CONTACTS:
    ----------------                           ------------------
    Endologix, Inc.                            The Ruth Group
    John McDermott, CEO                        Nick Laudico (646) 536-7030
    (949) 595-7200                             Zack Kubow (646) 536-7020
    www.endologix.com

SOURCE Endologix, Inc.


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. EPSScentral Responds to Pandemic Alert
3. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
4. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
5. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
6. Roche responds to announcement of IDEAL hepatitis C trial results
7. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
8. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
9. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
10. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
11. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec 9, 2016 Research ... Screening Market - Forecast to 2021" report to their ... ... of open innovative models in the pharmaceutical and biotechnology industry ... and rising government funding. Emerging markets and growing research activities ...
(Date:12/9/2016)...  RxWiki Inc., a digital health company that powers ... thousands of pharmacies through its Digital Pharmacist SaaS platform, ... "50 on Fire" Award in the Health and Life ... the award as one of Austin,s fastest growing companies," ... RxWiki. "Our platform gives independent retail pharmacies the digital ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, ... AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) ... ,LpxC, for the treatment of bacterial infections including ... been recognized as an attractive antibacterial target for ... lack of suitable chemical starting points has hampered ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman ... and outserts. As a means of expanding capabilities Flottman has added a ... to individually code professional inserts (PIs) and patient package inserts (PPIs) that will ...
(Date:12/9/2016)... , ... December 09, 2016 , ... An inventor from ... to safely ride all types of amusement park rides. , The patent-pending SAFETY STRAP ... is easy to use and could be set up in a matter of minutes, ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying ... Va. "I thought that if the nebulizer had a more child-friendly design, then children ... , He developed the patent-pending NEBY to avoid the need to deliver medication via ...
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
Breaking Medicine News(10 mins):